Company

Mission

Tetrahedron is commited to maintain or restore a healthy life and wellness by designing and developing new active and innovative micronutrients for nutritional, cosmeceutical and biomedical applications.

These active ingredients are :

  • Natural compounds, such as L-ergothioneine, for which Tetrahedron developed new and sustainable processes allowing their industrial production. Tetrahedron is the only company which provides pure L-ergothioneine in bulk quantities, as Ergoneine® for Nutrition and as Bioneine® for Cosmetics.
  • Original molecules derived from natural compounds, such as NutraSelen®, a new precursor of L-selenomethionine, providing proprietary compounds.

 

History

Tetrahedron is a Research & Innovation company designing and developing its own products portfolio from lab to market.

  1. Tetrahedron was funded on 2003 by Jean-Claude Yadan, Ph.D. in Medicinal Chemistry, Irene Erdelmeier, Ph.D. in Organic Chemistry, and Marc Moutet, Ph.D. in Biochemistry.
  2. In 2004 Tetrahedron filed its first patent on a new series of organic selenium-containing molecules as source of L-selenomethionine, the natural source of selenium for humans and animals.
  3. In 2008 Tetrahedron filed its third patent on an unique technology of selenomethionine-enrichment for Probiotics such as Lactobacillus.
  4. In 2009 NutraSelen®, the first Tetrahedron’s proprietary product, has been licensed worldwide to Adisséo, the international leader company in the feed market for the animal nutrition. Adisséo launched Selisséo, a feed additive containing NutraSelen in 2014.
  5. In 2009 Tetrahedron filed its fourth patent on a biomimetic process for the synthesis of L-ergothioneine.
  6. In 2009 Tetrahedron filed its fifth patent on a new process for the synthesis of L-thiohistidine.
  7. In 2012 Tetrahedron performed the industrial manufacturing of L-ergothioneine under the GMP compliance.
  8. in 2014 Tetrahedron filed a patent on a new series of antioxidants.
  9. in 2014 Tetrahedron filed a patent on a new series of anti-cancer agents for pharma application.
  10. In 2015 Tetrahedron got the self-affirmed GRAS status in USA for its food supplement ERGONEINE®, a new highly pure source of L-ergothioneine for the nutrition market.
  11. In 2018 Tetrahedron got the authorization from the European Commission for the Novel Food status for its food supplement ERGONEINE® for the general population.

 

Management Team

The Management Team has an experience of over 30 years in designing and managing R&D projects in Cosmetics, Diagnostics, Nutrition and Pharma.

Jean-Claude YADAN, Ph.D. in Medicinal Chemistry (1983) – Co-Founder and President

After working for Roussel-Uclaf as medicinal chemist, Jean-Claude co-founded Bioxytech in 1989, a biotech company focused on Free Radical Biology. Jean-Claude led R&D projects within Bioxytech and then Oxis SA and acted as Chief Scientific Officer and Managing Director of Oxis SA. Jean-Claude co-created Analytics Biophysics International in 1998, a CRO specialized in Bioanalytics and in 2001 co-created Expertise and Consulting, a CRO in Medicinal Chemistry.
He is the author of 20 patents and 35 international publications.

Irene ERDELMEIER, Ph.D. in Chemistry, Co-founder and Board Member

Following her PHD at Darmstadt Polytechnic Irene headed the department of Chemistry at Oxis SA. She then joined L’Oréal as senior researcher. Irene joined Expertise and Consulting as Director of Chemistry department before co-founding Tetrahedron.
She is the author of 16 patents and 22 international publications.

Marc MOUTET, Ph.D. in Biochemistry, Co-founder and Board Member

After several positions at L’Oréal and Helena Rubinstein, Marc headed the department of Biology at Oxis SA and Expertise and Consulting before co-funding Tetrahedron SAS.
He is the author of 12 patents and 30 international publications.

Jean-François LE BIGOT, Ph.D., Board Member

Jean-Francois Le Bigot started his industrial career at Sandoz Laboratories (now Novartis) as Head of Experimental Biology and then Director of Pre-Clinical Development in France. He is the former President, CEO and shareholder of Citoxlab Group, one of the leading international non-clinical Contract Research Organizations (CRO). From 1987 to 2019, Jean-Francois Le Bigot transformed CIT, a single site French non-clinical CRO with 120 staff, into the internationally recognized Citoxlab brand that includes today 8 research centers located in 5 countries and employs more than 1 500 people.
Co-author of 57 international publications.